Immunogenicity Screening Test: Principles, Methods, Standards, and Applications

Immunogenicity screening tests are laboratory evaluations designed to detect and characterize unwanted immune responses triggered by medical device materials, biomaterials, and biopharmaceutical products. Performed in accordance with ISO 10993-20 and related international standards, these tests generate essential safety data for risk management, design optimization, and regulatory submissions worldwide. This article explains the principles, sample types, testing items, analytical methods, and typical applications of immunogenicity screening.

Technical Overview

Immunogenicity refers to the capacity of a foreign substance, such as a device material, extractable chemical, or therapeutic protein, to provoke an immune response in a patient. Uncontrolled immune reactions to medical products can range from transient inflammation and hypersensitivity to severe outcomes such as complement-mediated pseudoallergy, immune complex disease, loss of therapeutic efficacy, or life-threatening anaphylactoid reactions. Immunogenicity screening tests therefore form a critical component of the biological safety evaluation program for any product that contacts body tissues, blood, or mucosal surfaces.

For medical devices, the governing framework is provided by ISO 10993-20, which addresses immunotoxicology testing within the broader risk management process defined in ISO 10993-1. The standard introduces a tiered evaluation philosophy: initial screening assays detect signals of immune perturbation, and follow-up functional studies are triggered only when screening results, device characteristics, or clinical use conditions indicate a need. The type, extent, and duration of immune contact with device materials are assessed using the medical device immune contact index (MDICI) concept to tailor the depth of testing.

Screening evaluates several arms of the immune system in parallel:

• Innate immune activation, including complement cascade activation and inflammatory cytokine release
• Humoral immunity, including immunoglobulin production and anti-material or anti-drug antibody formation
• Cellular immunity, including T-lymphocyte activation, proliferation, and immune cell subset changes
• Hypersensitivity potential across all four Gell-and-Coombs types, from immediate IgE-mediated reactions to delayed T-cell-mediated contact sensitization

For biopharmaceuticals and drug-device combination products, immunogenicity assessment follows complementary principles described in ICH S6 and ICH S8 and in regional guidance issued by major regulatory authorities, with a central focus on the detection and characterization of anti-drug antibodies. Because immune reactions are often idiosyncratic and difficult to predict from chemical structure alone, empirically validated screening assays remain the foundation of any immunogenicity risk assessment.

Testing Samples

Medical Device Extracts

Extracts are the most common test articles for device screening. Samples are prepared according to ISO 10993-12 using polar solvents (such as saline or culture medium) and non-polar solvents (such as sesame oil), with extraction ratios and conditions selected based on the device geometry, material thickness, and clinical exposure duration. Extraction temperatures typically range from 37 °C for thermolabile polymers to 121 °C for elastomers intended for steam-sterilized applications.

Intact Devices and Material Coupons

Where extraction may not represent real-world exposure, testing is performed by direct contact or through incubation of the intact device, cut material coupons, or representative surface areas with human serum, plasma, or peripheral blood mononuclear cells (PBMCs). This approach is particularly relevant for blood-contacting devices such as oxygenators, hemodialysis membranes, and intravenous catheters.

Biopharmaceutical Products

Therapeutic proteins, monoclonal antibodies, peptides, and nucleic acid-based products are tested as formulated drug substances or drug products. Serial dilutions covering the clinically relevant concentration range are evaluated alongside matrix-matched controls to account for interference from formulation excipients and endogenous serum components.

Drug-Device Combination Products

Coated stents, drug-eluting systems, prefilled syringes, and combination products incorporating leachables or novel excipients are tested by integrating device extract assessment with drug substance evaluation, ensuring that neither the device platform nor the active component introduces unanticipated immune liabilities.

Process Contact Materials and Leachables

Filters, tubing, elastomeric closures, and packaging components used in manufacturing or storage are screened for extractable and leachable compounds with immunostimulatory or sensitizing potential, supporting overall contamination and compatibility control strategies.

Testing Items

A comprehensive immunogenicity screening panel is assembled from the following categories, selected according to the product type and its intended clinical exposure:

• Complement activation markers: C3a, C5a, iC3b, Bb, C4d, and the terminal complement complex SC5b-9, quantified in human serum or plasma after contact with the test article
• Inflammatory cytokines and chemokines: IL-1β, IL-6, IL-8, TNF-α, IL-2, IL-4, IL-10, IFN-γ, and GM-CSF released from stimulated human PBMCs or whole blood
• Anti-drug antibody (ADA) parameters: screening binding antibodies, confirmatory antibodies, antibody titers, isotype characterization, and neutralizing antibody (NAb) activity
• Immunoglobulin classes associated with hypersensitivity: IgE for immediate-type reactions and specific IgG or IgM binding antibodies
• Lymphocyte function: proliferation indices, stimulation indices, and activation marker expression, including CD69, CD25, and HLA-DR
• Immune cell phenotyping: relative and absolute counts of lymphocyte subsets, monocytes, and natural killer (NK) cells, and NK cell cytotoxic activity
• Dermal sensitization potential: delayed-type hypersensitivity induction and elicitation responses
• Systemic immune signals: anaphylactoid reaction scoring, immune complex formation, and acute phase protein changes

Each testing item is linked to a defined immune mechanism, which allows investigators to interpret positive signals mechanistically rather than merely descriptively, and to design rational follow-up studies when warranted.

Testing Methods

In Vitro Complement Activation Assay

Test articles or extracts are incubated with pooled normal human serum or plasma under controlled temperature and agitation conditions. Complement split products generated during incubation, principally C3a, C5a, and SC5b-9, are quantified by enzyme-linked immunosorbent assay (ELISA). Zymosan or cobra venom factor serves as a positive control, while buffer-incubated serum provides the negative baseline. Results are expressed as concentration values and as fold-changes relative to controls, with reference to acceptance limits widely applied for blood-contacting devices under ISO 10993-4 and ISO 10993-20.

Cytokine Release Assay

Human PBMCs or diluted whole blood from multiple donors are exposed to serial dilutions of the test article. Secreted cytokines are measured in culture supernatants using ELISA or multiplex bead-based platforms. The use of multiple donors captures inter-individual immunological variability, and potent positive controls such as lectins or superantigens are included to verify cell responsiveness.

Lymphocyte Proliferation Assay

PBMCs are cultured with the test article for several days, and proliferation is quantified by tritiated thymidine incorporation, bromodeoxyuridine (BrdU) incorporation, or carboxyfluorescein succinimidyl ester (CFSE) dilution analyzed by flow cytometry. A stimulation index above the predefined threshold indicates that material-derived compounds act as T-cell mitogens or antigens, signaling a need for further hypersensitivity characterization.

Anti-Drug Antibody Testing Strategy

Biopharmaceutical immunogenicity follows a validated multi-tiered scheme: a screening assay detects low levels of binding antibodies with a drug-tolerant and sensitive method; a confirmatory competition assay verifies specificity; titration establishes antibody levels; and a cell-based neutralizing antibody assay determines whether antibodies block pharmacological activity. Ligand-binding platforms, electrochemiluminescence assays, and surface plasmon resonance techniques are commonly used to support assay sensitivity, drug tolerance, and matrix robustness.

In Vivo Hypersensitivity Models

Where in vitro data are insufficient, delayed-type hypersensitivity is evaluated using the guinea pig maximization test or the Buehler occluded patch method, which classify materials as sensitizing or non-sensitizing according to ISO 10993-10. The murine local lymph node assay (LLNA) offers a refinement alternative by measuring lymph node cell proliferation and is accepted by major regulatory authorities. Immediate-type hypersensitivity may be assessed with passive cutaneous anaphylaxis models when IgE-mediated risk is suspected.

Study Design and Quality Controls

All assays are performed with documented positive and negative controls, predefined acceptance criteria, and blinded sample coding where feasible. Method validation establishes precision, accuracy, specificity, and interference resistance for each matrix. Testing conducted in accredited third-party laboratories under GLP or ISO/IEC 17025 quality systems ensures that the resulting data are suitable for inclusion in regulatory submissions.

Applications

Immunogenicity screening data support decision-making across the entire product lifecycle:

• Regulatory submissions for device registration and market clearance in major jurisdictions, including premarket notifications and approvals in the United States, conformity assessment under the EU Medical Device Regulation, and registration dossiers in China, Japan, and other markets
• Biocompatibility documentation for blood-contacting devices such as hemodialyzers, extracorporeal circulation tubing, oxygenators, blood bags, cell separation columns, vascular grafts, stents, and heart valves
• Safety evaluation of long-term implants, including orthopedic, dental, cardiovascular, and ophthalmic devices with permanent patient contact
• Comparability exercises for biosimilars and manufacturing process changes affecting therapeutic proteins
• Material selection during research and development, allowing early elimination of polymers, additives, sterilization residues, or coatings with immunostimulatory potential
• Root cause investigation of adverse event signals in post-market surveillance and complaint handling
• Vendor qualification for elastomers, plastics, and process contact materials used in sterile fluid pathways

By integrating screening results with chemical characterization and toxicological risk assessment, manufacturers can construct a defensible, science-based justification of immunological safety and reduce the likelihood of late-stage development failures.

FAQ

When is immunogenicity screening required for a medical device?

Screening is expected whenever a device or its leachable components contact immune-relevant tissues, blood, or lymph, particularly for prolonged or repeated exposure, for blood-contacting devices, for implanted devices, and whenever novel materials, coatings, or leachables raise unresolved immunological questions. The evaluation strategy is proportionate to the type, extent, and duration of contact as assessed under ISO 10993-1 and ISO 10993-20.

Which standards govern immunogenicity screening?

The principal standard for medical devices is ISO 10993-20, which is applied together with ISO 10993-1 for test selection, ISO 10993-12 for sample preparation, ISO 10993-10 for sensitization, and ISO 10993-4 for blood interaction. For biopharmaceuticals, ICH S6 and ICH S8, together with regional immunogenicity guidance from major regulatory authorities, define expectations for anti-drug antibody evaluation.

What sample quantities and forms are needed for testing?

Requirements depend on the selected assay panel. Extract-based assays require representative device sections or a defined surface area compatible with standard extraction ratios, while direct-contact assays require intact devices or coupons sized to the culture format. For biologics, sufficient drug substance or product is needed to prepare serial dilutions spanning supra-therapeutic and therapeutic concentrations.

How long does a screening program typically take?

In vitro complement, cytokine, and proliferation assays are generally completed within a few weeks, including donor blood procurement and analysis. In vivo sensitization studies such as the guinea pig maximization test require six to eight weeks of animal phases plus histopathology and reporting. Multi-tier ADA testing for biologics adds method validation time and is typically scheduled across the development program.

What is the difference between screening and comprehensive immunotoxicity testing?

Screening consists of relatively rapid, sensitive assays designed to detect immune perturbation signals, such as complement activation, cytokine release, and antibody formation. Comprehensive, or functional, testing follows when screening indicates concern and evaluates integrated immune function, including T-cell-dependent antibody response, NK cell activity, and host resistance models, providing a deeper mechanistic understanding of the identified risk.

How are positive screening results handled?

A positive signal triggers a structured follow-up: confirmation in independent assay runs, chemical characterization to identify candidate causative compounds, risk-benefit assessment in the context of clinical use, and, where necessary, material reformulation or process modification. Justification may also derive from existing clinical data if the same materials have a documented history of safe use.

Can immunogenicity screening be combined with other biocompatibility tests?

Yes. Complement activation is frequently evaluated alongside hemolysis, thrombosis, and coagulation testing within a hemocompatibility panel, while cytokine release studies can share sample preparation with cytotoxicity and irritation evaluations. An integrated testing strategy reduces sample consumption, shortens timelines, and produces a coherent biocompatibility dossier.